Search results
Added:
5 years ago
Idarucizumab for Dabigatran Reversal: Full Cohort Analysis - Animated Video
View more
Author(s):
A John Camm
Added:
8 years ago
Author(s):
Demosthenes G Katritsis
Added:
3 years ago
Reviewing recent literature of advances in arrhythmia therapy, I have found most interesting the emergence of antidotes, both general and specific, for the non-vitamin K antagonist oral anticoagulants (NOACs). NOACs offer a relative 50 % reduction in the risk of intracranial haemorrhage and haemorrhagic stroke compared with warfarin that is also maintained in the elderly. There are no clear…
View more
Author(s):
Nur A Rahmat
,
Gregory YH Lip
Added:
3 years ago
Until recently, the vitamin K antagonist (VKA, e.g. warfarin) class of drugs was the only oral anticoagulant in use. VKAs have important inter- and intra-patient variability, influenced by diet, alcohol and drugs; thus, regular anticoagulation monitoring is necessary. Indeed, VKAs offer their best efficacy and safety when the average time in therapeutic range (TTR) is >65–70 % in a particular…
View more
Author(s):
Katrina Mountfort
,
Paulus Kirchhof
,
A John Camm
,
et al
Added:
2 years ago
Author(s):
Leo Buckley
,
Ahmed Aldemerdash
Added:
3 years ago
Cardiovascular disease is the leading cause of death in the US.1,2 Although advances in the prevention and treatment of cardiovascular disease have contributed to a decline in mortality rates, this favorable trend has slowed over the past several years.3 Recently, however, a revival of cardiovascular drug development has introduced new treatment options to the market, with several promising…
View more
Added:
3 years ago
Barcelona, Spain – 19 March 2018:A new version of the EHRA Practical Guide on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation is published online today inEuropean Heart Journaland an executive summary inEP Europace, and presented at EHRA 2018, a European Society of Cardiology (ESC) congress.1–3The guide, now in its third edition with more than…
View more
Author(s):
George D Katritsis
,
Demosthenes G Katritsis
Added:
3 years ago
Atrial fibrillation (AF) is associated with a fivefold increased risk for stroke, a twofold increased risk for dementia, and a tripling of risk for heart failure,1,2,3 while AF genetic risk is strongly associated with cardioembolic stroke.4In the Framingham Heart Study the percentage of strokes attributable to AF increases steeply from 1.5% at 50–59 years of age to 23.5% at 80−89 years of age.5,6…
View more
Author(s):
Antoni Martínez-Rubio
,
Mario DiazNuila-Alcazar
,
Anna Soria Cadena
,
et al
Added:
3 years ago
Atrial fibrillation (AF) is the most commonly encountered arrhythmia in clinical practice in Western countries. The prevalence of AF depends on the population studied1 and especially on age.2–9 It is affected by increasing longevity and is modulated by the prevalence of cardiovascular risk factors, especially arterial hypertension and related habits. In Spain, for example, the prevalence of AF…
View more